For unknown reasons, the highest incidence of osteoporosis is found in northern Europe. In these populations, the sunlight exposure is limited and the vitamin A intake is high. The interaction between vitamin A and D has been the subject of several in vitro and animal studies. We have studied the acute effects of vitamin A and D on calcium homeostasis in 9 healthy human subjects. We compared the effect of ( 
INTRODUCTION
T HE INCIDENCE of osteoporosis, measured as the rate of the osteoporosis-related hip and distal forearm fractures, is remarkably high for both men and women in the Scandinavian countries. (1, 2) In this area the intake of retinol is high.
Hypervitaminosis A is known to cause accelerated bone metabolism and spontaneous fractures in laboratory animals (4, 5) and a high dietary intake has been associated with the development of osteoporosis. (6) Vitamin A has been suggested to interfere with the action of vitamin D. The active metabolites of vitamin A and D, retinoic acid (RA) and 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ], regulate gene expression through nuclear receptors in the steroid-thyroid hormone receptor family. The vitamin D receptor (VDR) and the RA receptors (RARs) bind to their target genes as heterodimers, consisting of VDR or RAR together with one of the retinoid X receptors (RXRs). Binding of 1,25(OH) 2 D 3 to VDR-RXR activates the complex, resulting in initiation or suppression of gene transcription. (7) The RXR ligand 9-cis-RA has been shown to be a modulator of VDR-RXR action in vitro, possibly by interacting with receptor dimer formation. (8) In vitro studies have variously indicated antagonistic, additive, or synergistic interaction between the vitamins. (9) In vivo, a high level of vitamin A intake is shown to reduce the toxicity associated with hypervitaminosis D in rats (10) and turkey poults (11) and increase the need for dietary vitamin D in chickens (12) and poults. (11) Hypervitaminosis D similarly diminishes vitamin A toxicity symptoms such as lowered bone ash in chickens. (13) Recently, in rats, an antagonistic relationship was shown in bones and intestines. (14) To investigate if vitamin A can antagonize the action of vitamin D in man, we have studied the acute effects of single doses of vitamin A and D on calcium homeostasis and bone resorption in healthy human subjects.
MATERIALS AND METHODS

Subjects
People working in our department were invited to participate in the study and 9 healthy subjects, 4 men and 5 women aged 24 -41 years (mean age, 28 years), were recruited. Their healthy status was assessed by an interview and potential subjects were excluded if they had a history of any illness affecting bone and mineral metabolism, any other chronic disease, or took any medication at the time of the study. The presence of any undiagnosed parathyroid disease was ruled out by the biochemical analyses of serum performed on the first reference blood sample. Informed consent was obtained from all subjects volunteering for the study, which was approved by the local ethical committee at Uppsala University Hospital.
Design
All subjects were studied on four different occasions during the period from September to November 1999. On every study occasion, the subjects took one of the following vitamin preparations: (i) 15 mg of retinyl palmitate, (ii) 2 g of 1,25(OH) 2 D 3 , (iii) 15 mg of retinyl palmitate plus 2 g of 1,25(OH) 2 D 3 (combined intake), or (iv) placebo. Vitamins and placebo were prepared as tablets and taken orally. The interval between the four occasions was always at least 14 days. This interval was chosen to avoid carryover effects and was based on the plasma half-life for retinyl palmitate (1.5-9.9 h (15) ) and 1,25(OH) 2 D 3 (5-8 h (16) ). The subjects took the vitamin preparations in a randomized, blinded order in which every subject had taken every vitamin preparation once when the study was completed. We chose 15 mg of retinyl palmitate because this corresponds to the amount of vitamin A in one serving of liver, (17) that is, the maximum vitamin A intake from dietary sources. The physiological vitamin D dose administered [2 g of 1,25(OH) 2 D 3 ] was chosen because it has been reported previously to exert an acute effect on bone metabolism. (18, 19) Except for the vitamin intakes, the conditions were kept constant during the different study occasions and on every occasion the subjects went through the following protocol. On day 1, a blood sample was drawn through venous puncture at 8:00 a.m., after an overnight fast. This sample was used as a control sample for the postvitamin samples. The subjects were told not to perform any exhaustive exercises and not to eat any food with a high content of fatsoluble vitamins during day 1, but no other restrictions were asked for. At 10:00 p.m., the subjects had their randomized vitamin preparation, and from that moment on they were fasting until the scheduled breakfast the next morning. During day 2, blood samples were collected through an indwelling venous catheter. The first fasting sample was drawn at 8:00 a.m., and after that, the subjects had breakfast. Four more samples were drawn at 10:00 a.m., 12.00 noon, 2:00 p.m., and 4:00 p.m. and lunch was served after the noon blood collection. Standardized meals were served at the same time on every study occasion, and the subjects were not allowed to eat or drink anything but water, coffee, or tea between the meals. A morning urine sample was collected on day 2.
Biochemical analysis
Serum was obtained through centrifugation of the collected blood. Serum and urine were stored immediately in aliquots at Ϫ70°C until assayed for serum 1,25(OH) 2 
, S-retinyl esters, S-calcium, S-albumin, S-parathyroid hormone (PTH), and the degradation product of C-telopeptide of type I collagen (S-CrossLaps (20) ), and urine calcium (U-calcium) and U-creatinine. All samples from 1 individual were analyzed in the same assay to avoid interassay variability and both serum and urine samples were analyzed in duplicate.
Analyses of S-1,25(OH) 2 D 3 and S-retinyl esters were performed for the 8:00 a.m. fasting samples only. S-1,25(OH) 2 D 3 was immunoextracted before radioimmunoassay quantification was performed. The kit used (IDS Ltd., Boldon, UK) had an intra-assay variation of 8%. Analysis of retinyl esters was done by AS Vitas (Oslo, Norway) on serum shielded from light. Two hundred microliters of serum or standard solutions was mixed with 600 l of 2-propanol and centrifuged at 4000g. The supernatant was analyzed by liquid chromatography on a HP1100 highperformance liquid chromatography (HPLC) system furnished with a Supersphere 100 RP-18 column (Agilent Technologies, Palo Alto, CA, USA) and detected at 325 nm with a UV detector. The mobile phase consisted of methanol-dichloromethane and the injection volume was 100 l. A three-point calibration curve constructed with albumin solutions enriched with different concentrations of retinyl palmitate was used to quantify all retinyl esters. The intra-assay variation was 5.1%.
S-calcium, S-albumin, S-PTH, and S-CrossLaps, were analyzed at all sampling points. S-calcium (intra-assay variation, 1.5%) and S-albumin (intra-assay variation, 4.5%) was determined by complexometric, colorimetric assays using the spectrophotometric Hitachi 717 autoanalyzer according to the manufacturer's instructions (Roche, Stockholm, Sweden). Briefly, for S-calcium, serum was alkalinized and heated to 37°C before addition of the complex forming chromogen o-cresolphthalein and the calcium concentration was then determined at 546 nm. For S-albumin, serum was first acidified. The complex forming substrate bromcresol green was then added and the albumin concentration was determined at 570 nm. S-calcium levels were adjusted for the concomitant S-albumin. Intact S-PTH was measured by a sandwich radioimmunometric method (intraassay variation, 3.4%; Nichols Institute, San Juan Capist-
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rano, USA). For analysis of the bone resorption marker S-CrossLaps a sandwich ELISA kit, Serum CrossLaps OneStep ELISA (intra-assay, CV 5.4%; Osteometer BioTech A/S, Herlev, Denmark) was used. U-calcium was quantified by atomic absorption spectrophotometry using a GBC Avanta ⌺ autoanalyzer (Nordlab AB, Stockholm, Sweden) according to the manufacturer's instructions (intra-assay variation, 2.2%). Briefly, the atomic absorption was measured at 422.7 nm, after acidification of the urine. U-calcium levels were corrected for U-creatinine, measured by a kinetic colorimetric assay using the Hitachi 717 autoanalyzer (intra-assay variation, 2.2%). Briefly, the urine was alkalinized and after addition of picric acid, the complex formed was determined at 505 nm. The analyses of S-calcium, S-albumin, S-PTH, U-calcium, and U-creatinine were performed as a part of the clinical routine at the Department of Clinical Chemistry, University Hospital, Uppsala, Sweden.
Statistical analysis
The StatView 4.5 software (Abacus Concepts, Berkeley, CA, USA) was used for all statistical analyses. In every case, a value of p Ͻ 0.05 was considered significant. For evaluation of vitamin uptake, mean values of S-1,25-(OH) 2 D 3 and S-retinyl esters before and after vitamin intake were calculated and compared with the Wilcoxon signed rank test. To analyze the effect of vitamin intake on S-calcium, we used the five serum samples from day 2 (8:00 a.m.-4:00 p.m.). As a substitute for measurement of the area under curve, we calculated the mean level of serum calcium in the five samples. This was done separately for each vitamin intake and for placebo. The effect of vitamin intake was defined as the mean serum calcium level after vitamin intake minus the mean level after placebo. Thus, for every individual we calculated three values, corresponding to the effect of retinyl palmitate intake, 1,25(OH) 2 D 3 intake, and combined intake, respectively. These effect values were statistically analyzed using the Wilcoxon signed rank test. The effect of vitamin intake on S-PTH and S-CrossLaps was analyzed and presented in exactly the same way. The effect of vitamin intake on U-calcium excretion was evaluated by the Wilcoxon signed rank test. 
RESULTS
Vitamin intake results in increased serum levels of 1,25(OH) 2 D 3 and retinyl esters
Retinyl palmitate diminishes the 1,25(OH) 2 D 3 effect on S-calcium
Serum levels of calcium and PTH are shown in Fig. 1 . As expected, we see increased S-calcium and concomitantly decreased S-PTH after intake of 1,25(OH) 2 D 3 . In contrast, S-calcium is decreased after retinyl palmitate intake, whereas S-PTH is not affected. After the combined intake, the rise in S-calcium is significantly lower compared with the rise after intake of 1,25(OH) 2 D 3 alone. For S-PTH, no significant effect of retinyl palmitate is found, and levels are similar to those after intake of 1,25(OH) 2 D 3 only. For the bone resorption marker CrossLaps (Fig. 2) and for U-calcium (Table 2) , none of the vitamin preparations produced an effect significantly different from placebo.
DISCUSSION
Here, we show that retinyl palmitate can antagonize the S-calcium response elicited by intake of 1,25(OH) 2 D 3 . The theoretical basis for a hypothesis of such an interaction is provided by the VDR-RXR heterodimer mediating the molecular action of 1,25(OH) 2 D 3 and the allosteric receptor ligand interactions that have been shown in vitro. (8) Previously, we have reported an antagonistic effect of RA on 1,25(OH) 2 D 3 -induced bone resorption in vitro. (21) In this study, we see no effect on the bone resorption as measured by the bone resorption marker S-CrossLaps (Fig. 2) .
Long-term excess of vitamin D leads to hypercalciuria and it is controversial whether this phenomenon is caused 
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by the hypercalcemia secondary to increased intestinal calcium absorption or bone resorption or if it is caused by a direct effect on renal reabsorption of calcium. (22) A few in vitro and animal studies show an acute effect of vitamin D on renal calcium reabsorption but it is not clear if the effect is direct or mediated via PTH. (22) (23) (24) Little is known about this effect in humans. In our study, the average U-calcium after vitamin D intake apparently is increased but because of the large SD, which is not simply caused by an outlier, the difference is not statistically significant. Therefore, we cannot conclude that the vitamin intakes have affected renal calcium reabsorption.
Absorption competition between the vitamins is another possible mechanism for interaction. Both vitamin A and D are fat soluble and the important dietary sources of vitamin D, dairy products, fatty fish, and fortified foods also are rich in vitamin A. (17) In our study, S-1,25-(OH) 2 D 3 and S-retinyl esters increased significantly after intake of the corresponding vitamin. There was a large interindividual variation in retinyl esters, both regarding the absolute level and the degree of increase after vitamin intake. All individuals increased their vitamin levels, indicating that the vitamin absorption was efficient. Neither S-1,25(OH) 2 D 3 nor S-retinyl esters seemed to be affected by simultaneous intake of the other vitamin. However, because of the large variation among the subjects, we cannot with certainty exclude that the antagonistic effect was exerted at the level of vitamin absorption.
In summary, the antagonistic effect on S-calcium is not caused apparently by a direct effect on vitamin absorption or bone resorption and it is not mediated through renal calcium filtration or reabsorption. Instead, our data suggest that the antagonism may be exerted at the level of intestinal calcium absorption. Further studies are needed to confirm the mechanism of the antagonism.
Serum levels of calcium, vitamin D, and vitamin A can influence PTH secretion from the parathyroid glands. 1,25(OH) 2 D 3 exerts an immediate (seconds (25) ) suppressive
FIG. 1.
Average S-calcium and S-PTH levels after vitamin intake in 9 subjects. Vitamins were ingested at 10:00 p.m. the night before measurements, and a reference blood sample (ref) was taken at 8:00 a.m. the morning before vitamin intake. The effects were calculated as the difference between average serum level after each vitamin intake and placebo and were compared with the Wilcoxon signed rank test. 
FIG. 2.
Average S-CrossLaps levels after vitamin intake in 9 subjects. Samples were collected and analyzed as described in Fig. 1 
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effect on PTH secretion via increased calcium levels, (26) whereas the direct effect on parathyroid tissue leads to decreased PTH secretion only after a lag period of 12-18 h or more. (27) (28) (29) (30) (31) Thus, the changes in PTH we see after intake of 1,25(OH) 2 D 3 are likely to be reflections of changes in S-calcium rather than direct regulation of PTH secretion. Similarly, the directly suppressive effect on PTH expression in vitro that has been reported for RA is delayed at least 12 h, (32) and we see no effect of retinyl palmitate on PTH levels in our study.
We report decreased S-calcium after retinyl palmitate intake. Consistently, a decreased S-calcium is seen in the acute phase of isotretinoin treatment. (33) However, hypercalcemia has been reported in cases of chronic vitamin A intoxication. (34 -36) Therefore, we hypothesize that decreased serum calcium is the acute physiological response to vitamin A intake while hypercalcemia is a phenomenon caused by a direct effect of vitamin A on bone metabolism, leading to increased bone resorption.
Recently, Rohde et al. (14) reported that retinyl acetate antagonizes the mineralizing effect of vitamin D 2 in rats. This antagonistic effect was more dramatic as the amount of dietary vitamin D 2 was diminished. Moreover, at a normal level of calcium intake the S-calcium response to a low dose of vitamin D 2 was eliminated by increased intake of retinyl acetate. This effect was not seen in rats fed a rachitogenic diet, indicating that an antagonism was exerted at the level of intestinal absorption. Our findings are in agreement with these results.
Increasing the efficiency of the small intestine to absorb dietary calcium is the major mechanism by which vitamin D maintains calcium homeostasis and 1,25(OH) 2 D 3 is the hitherto only recognized hormonal stimulus of active intestinal calcium absorption. (23) A significant proportion of patients with osteoporosis have malabsorption of calcium (37) and fail to adapt to a low-calcium diet by increasing S-1,25(OH) 2 D 3 . (37, 38) Furthermore, hypovitaminosis D is common in many populations (39, 40) and a seasonal variation in bone mineral density (BMD), possibly related to serum levels of 25(OH)D, has been detected in areas where sunlight is incapable of producing sufficient amounts of vitamin D during the winter. (41, 42) In Scandinavia the average daily intake of vitamin D is below recommended levels in many groups (43) (44) (45) (46) and the limited sunlight exposure increases the risk for hypovitaminosis D. In rat the antagonistic effect of vitamin A was seen at low intake levels of vitamin D and calcium. (14) We hypothesize that the high intake of vitamin A in Scandinavia may aggravate further the effect of hypovitaminosis D on calcium absorption.
Vitamin A is stored in the liver and is secreted slowly from the body. Because of accumulation of vitamin A in the body, chronic exposure can produce toxicity at a much lower dose than acute toxicity, which is elicited by a short period of high-dose exposure. The safe dose for less obvious symptoms such as bone loss is not known. Previously, we have found an association between reduced BMD and an intake of preformed retinol exceeding 1.5 mg/day. The average dietary intake of preformed retinol in Sweden is 1.0 mg for men and 0.775 mg for women. (47) The average total dietary vitamin A intake is 2.2 times the recommended daily intake stated by Food and Agricultural Organization/World Health Organization (FAO/WHO; 600 g retinol equivalents [RE] for men, 500 g RE for women (48) ). A limitation of our study is that only one dose is being tested. Further evaluation of the effect of different doses of vitamin A, emphasizing the important issue of the lowest safe level of intake, is suggested. Studies of the chronic effects of the observed antagonism, concerning the influence on the action on vitamin D but also to the potential adverse effect on the skeleton, are desirable also.
In conclusion, we have found that vitamin A antagonizes the serum calcium response to vitamin D in man, consistent with the hypothesis of an antagonistic relationship between the vitamins. 
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